Free Trial

NEXGEL Q2 2023 Earnings Report

NEXGEL logo
$4.73 +0.11 (+2.38%)
(As of 12/20/2024 05:31 PM ET)

NEXGEL EPS Results

Actual EPS
-$0.12
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

NEXGEL Revenue Results

Actual Revenue
$1.17 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

NEXGEL Announcement Details

Quarter
Q2 2023
Time
N/A
First JFK… next Elon? (Ad)

Today, I have another controversial prediction. One which I will take no pleasure in seeing come true. See, even with President Trump returning as the leader of our free country, I believe Elon Musk is in mortal danger.

I share with you in this special investigative documentary.

NEXGEL Earnings Headlines

This is the worst sign for the U.S. stock market in 50 years
The Dow recently posted its worst losing streak since 1974. And one of America's most accurate analysts now says this is just the beginning of a new crisis that could be worse than the COVID crash, the dot-com crash, and even the Great Depression. Introducing "The Dead Zone"
NexGel, Inc. Reports Increased Revenue Amid Ongoing Challenges
See More NEXGEL Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like NEXGEL? Sign up for Earnings360's daily newsletter to receive timely earnings updates on NEXGEL and other key companies, straight to your email.

About NEXGEL

NEXGEL (NASDAQ:NXGL) manufactures high water content, electron beam cross-linked, and aqueous polymer hydrogels and gels. Its products are used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company was formerly known as AquaMed Technologies, Inc. and changed its name to NEXGEL, Inc. in November 2019. The company was incorporated in 2009 and is based in Langhorne, Pennsylvania.

View NEXGEL Profile

More Earnings Resources from MarketBeat

Upcoming Earnings